Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Long-Term Safety Study of Inhaled Nitric Oxide (iNO) for PAH for Subjects in the PULSE-PAH-006 and PULSE-PAH-004 Studies Who Continue to Need iNO Therapy

NCT02652429 is registered in ClinicalTrials.gov with Bellerophon Pulse Technologies as lead sponsor.

NCT NCT02652429
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02652429 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Long-Term Safety Study of Inhaled Nitric Oxide (iNO) for PAH for Subjects in the PULSE-PAH-006 and PULSE-PAH-004 Studies Who Continue to Need iNO Therapy
Lead sponsor
Bellerophon Pulse Technologies
Phase
Phase 3
Overall status
Unknown status
Start date
March 31, 2016
Completion date
December 31, 2023
Enrollment
22 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary arterial hypertension